Mirimus expands their platforms for RNAi and CRISPR.
Through Mirimus' expertise with RNAi and CRISPR/Cas9 technologies, we are now utilizing our novel platform to serve as entry into the generation of higher organisms such as rats with reversible gene silencing capabilities in the near future.
Undoubtedly, extending our RNAi technology into other species will transform scientific research by providing model systems in which disease and therapeutic outcomes more closely resemble their human counterparts.
The ability to better model clinical disorders and evaluate genetic and environmental stimuli in advanced mammalian species will increase our confidence in predicting drug responses in humans and push drug discovery research into a new era.